最新报道:Pharmaceutical companies are pressing the EU and U.S. for clearer tariff policies under their new trade deal, warning that uncertainty could disrupt supply chains and raise drug costs. Industry leaders argue that ambiguous rules on duties for medicines and ingredients may lead to higher prices for patients and slower market access. The EU-U.S. Trade and Technology Council is expected to address these concerns in upcoming negotiations.